Biopharmaceuticals

Sterne Kessler’s biopharma industry team counsels clients worldwide on IP strategy across medical and healthcare related applications of biotechnology.

Sterne Kessler works closely with biologic drug companies to develop robust, defensible patent portfolios that create substantial shareholder value. Our clients’ innovations span therapeutic antibodies, vaccines, nanomedicines, and related diagnostics that make personalized medicine a reality. We know biopharmaceuticals and we have been on the forefront of biopharma intellectual property from the very start.

The biotechnology practice at Sterne Kessler was established by Dr. Jorge Goldstein just as the biotech revolution was getting started. As the market expanded, so did our practice. We represent companies and research institutes of all sizes and levels, and they span, among others, the areas of:

  • Molecular and cell biology
  • Nanomedicine
  • Pharmacogenomics
  • Vaccines
  • Therapeutic antibodies
  • Nutraceuticals
  • Biologics and biosimilars

We prepare and prosecute patent applications before U.S. and foreign patent offices; conduct interferences, IPRs, and other patent office litigation; and lead district court and U.S. International Trade Commission litigations. For those collaborating, licensing, or commercializing innovations, we provide counseling regarding agreements and develop freedom to operate opinions. Additionally, we conduct IP due diligence to support our clients who are licensing or investing in promising new technologies.

We meet our clients’ needs with an integrated team of more than 70 attorneys and technical staff with advanced training that cuts across a variety of disciplines including:

  • Biochemistry
  • Bioinformatics
  • Computer-aided drug design
  • Enzymology
  • Gene therapy
  • Genetics
  • Genomics
  • Immunology
  • Medicinal chemistry
  • Microbiology
  • Molecular biology
  • Organic chemistry
  • Pharmacology
  • Physical chemistry
  • Virology

Related Resources

Webinar

2023 PTAB Year in Review: Analysis & Trends

February 7, 2024 1:00 PM - 2:00 PM PST

Webinar Recordings & Materials

2023 PTAB Year in Review: Analysis & Trends

February 7, 2024

Webinar Recordings & Materials

Federal Circuit IP Appeals: Summaries of Key 2023 Decisions

January 23, 2024

In the News

Patent Policy To Watch In 2024

Law360 January 1, 2024

Webinar

Patent Term Extension Considerations for BioPharma Patents

December 13, 2023 2:00 PM - 3:00 PM PST

Webinar Recordings & Materials

Patent Term Extension Considerations for BioPharma Patents

December 13, 2023

In the News

PTAB Denies Review Of Univ. Of Texas System Cancer Patent

Law360 November 27, 2023

Firm Announcements

Sterne Kessler Secures Denial of PGR for Largest Cancer Center in the US

Sterne, Kessler, Goldstein & Fox November 27, 2023

In the News

Delaware Jury: Guardant Willfully Infringed Patents With DNA Sequencing Kits

Mealey's Litigation Report: Intellectual Property, pub. 41094 November 16, 2023

Firm Announcements

Sterne Kessler Scores $83.4M Federal Jury Verdict for TwinStrand Biosciences, Inc.

Sterne, Kessler, Goldstein & Fox November 15, 2023

Firm Announcements

Sterne Kessler Scores $83.4M Federal Jury Verdict for TwinStrand Biosciences, Inc.

Sterne, Kessler, Goldstein & Fox November 15, 2023

Press Release

Ivy Estoesta Recognized as an INTA Rising Star

Sterne, Kessler, Goldstein & Fox November 1, 2023

Press Release

Directors Sterne and Goldstein Recognized in Who’s Who Legal Thought Leaders: USA 2024 Guide

Sterne, Kessler, Goldstein & Fox October 31, 2023

In the News

DNA Sequencing Patent Survives Guardant PTAB Challenge

Law360 October 11, 2023

Speaking Engagement

LSPN Chairman’s Opening Address and Closing Remarks

October 10, 2023 9:30 AM - 6:50 PM PST

Books and Chapters

U.S. Biotechnology Patent Law, 2023 ed.

Thomson Reuters September 8, 2023

Speaking Engagement

FDA and PTO Panel

July 1, 2023 9:45 AM - 10:45 AM PST

Speaking Engagement

Preparing for Biosimilar Carve Outs: Will Skinny Labelling Work for Biosimilars?

June 27, 2023 4:15 PM - 5:15 PM PST

Speaking Engagement

How to Pitch to Biotech VCs

June 1, 2023 9:00 AM - 10:00 AM PST

Speaking Engagement

Chairman’s Opening Address and Closing Remarks

May 3, 2023 9:00 AM - 5:00 PM PST

Speaking Engagement

2023 Focus on Pharma

April 14, 2023 8:30 AM - 6:00 PM PST

In the News

Second Wave of Biosimilar Cases Sharpens Patent Counsel Focus

Managing IP January 27, 2023

Press Release

Sterne Kessler Director Eldora L. Ellison Appointed to Advisory Council for the CAFC

Sterne, Kessler, Goldstein & Fox September 30, 2022

Bylined Articles

Watching the Pot™

Sterne, Kessler, Goldstein & Fox September 30, 2022

MarkIt to Market®

MarkIt to Market® – September 2022

September 30, 2022

Books and Chapters

U.S. Biotechnology Patent Law, 2022 ed.

Thomson Reuters August 31, 2022

Speaking Engagement

Advocating for Diversity in IP: Practical Ideas for Implementing Change

June 29, 2022 4:30 PM - 5:30 PM PST

In the News

WTO Waiver Spurs In-House Fears of Broader Deals

Managing IP June 29, 2022

In the News

New Trustees to Join Cornell Board

Cornell Chronicle June 2, 2022

Speaking Engagement

Chairman’s Opening Address and Closing Remarks

May 11, 2022 9:00 AM - 4:45 PM PST

Bylined Articles

Case Studies and Trends at the PTAB Involving 35 U.S.C. § 112

Sterne, Kessler, Goldstein & Fox March 7, 2022

Bylined Articles

Biologics at the PTAB: Statistics and Insights into Notable Biologics Decisions

Sterne, Kessler, Goldstein & Fox March 7, 2022

In the News

Pharma Turns to Trade Secrets and Open Source for Software

Managing IP December 9, 2021

In the News

Inside the Life of a Patent Prosecution Boss

Managing IP October 22, 2021

Books and Chapters

U.S. Biotechnology Patent Law, 2021 ed.

Thomson Reuters September 8, 2021

Bylined Articles

Waiving Covid-19 Vaccine Patents Won’t Solve the Global Need

Bloomberg Law August 17, 2021

Speaking Engagement

Comprehensive and Effective IP Due Diligence

June 17, 2021 12:20 PM - 1:10 PM PST

Speaking Engagement

Round Table Discussion: Litigation in an Age of Biologics Versus Biosimilars

April 15, 2021 11:55 AM - 1:00 PM PST

Podcast Recording & Transcript

Innovation Conversations: Dr. Claire Fraser

January 26, 2021

Press Release

Sterne Kessler Named Among 2021 “Best Law Firms” by Best Lawyers

Sterne, Kessler, Goldstein & Fox November 6, 2020

Webinar

Drug Development Pathway Series: Intellectual Property Workshop

October 28, 2020 4:00 PM - 5:00 PM PST

Press Release

Firm and Seven Directors Recognized in 2020 LMG Life Sciences Rankings

Sterne, Kessler, Goldstein & Fox P.L.L.C. October 6, 2020

In the News

In Case You Missed It: Hottest Firms And Stories On Law360

Law360 September 11, 2020

Bylined Articles

Patent License Considerations After Fed. Circ. Enbrel Ruling

Law360 September 4, 2020

Books and Chapters

U.S. Biotechnology Patent Law, 2020-2021 Edition

Thomson Reuters August 12, 2020

Bylined Articles

Biopharma Patentees Must Navigate Inherent Obviousness

Law360 June 23, 2020

Bylined Articles

Joint Research Considerations As Biotech Responds To Virus

Law360 April 27, 2020

Speaking Engagement

Pharma IPR Conference 2020

March 4, 2020 12:00 AM - 11:59 PM PST

Speaking Engagement

International IP Skills Summit (IIPSS)

February 26, 2020 12:00 AM - 11:59 PM PST

Bylined Articles

Fed. Circ. Amgen Biosimilar Ruling Raises IP Damages Risk

Law360 February 26, 2020

In the News

Federal Circuit Ruling Could Put Certain Drug Patents At Risk

Bloomberg Law December 31, 2019

Books and Chapters

U.S. Biotechnology Patent Law, 2019-2020 Edition

Thomson Reuters November 1, 2019

Press Release

Director Eldora L. Ellison, Ph.D. Receives Top Honor at 2019 LMG Life Sciences Awards

Sterne, Kessler, Goldstein & Fox P.L.L.C September 23, 2019

In the News

Cannabis Companies Gamble on Patents to Lure Possible Suitors

Bloomberg Law August 1, 2019

MarkIt to Market®

MarkIt to Market® – July 2019

July 31, 2019

Speaking Engagement

Summit on Biosimilars

June 24, 2019 1:30 PM - 2:30 PM PST

Global Patent Prosecution

Global Patent Prosecution Newsletter – June 2019

June 12, 2019

Bylined Articles

Cannabis Patenting at an All-Time High Despite Illegal Status

Sterne, Kessler, Goldstein & Fox P.L.L.C. June 12, 2019

Bylined Articles

Hemp Legalization and the International CBD Boom

Sterne, Kessler, Goldstein & Fox P.L.L.C. June 12, 2019

Bylined Articles

A Useful Roadmap for Claiming Cannabis Inventions

Sterne, Kessler, Goldstein & Fox P.L.L.C. June 12, 2019

Bylined Articles

IP’s Developing Role In Cannabis Business Strategy

Law360 June 11, 2019

Bylined Articles

Proposed BPCIA reforms: More music, same dance

Managing Intellectual Property May 16, 2019

Speaking Engagement

Biosimilars Commercialisation Summit

May 14, 2019

Speaking Engagement

13th Annual Paragraph IV Disputes

April 29, 2019

Speaking Engagement

2nd Annual Automotive Legal and IP World Summit 2019

March 27, 2019 12:00 AM - 11:59 PM PST

Bylined Articles

Biopharma Patent Applicants Should Consider a Rarely Used Strategy

Bloomberg Law March 18, 2019

PTAB Strategies and Insights

PTAB Strategies and Insights – January 2019

January 24, 2019

Bylined Articles

PTAB Only Partially Smokes Cannabis Patent

Sterne, Kessler, Goldstein & Fox P.L.L.C. January 24, 2019

Bylined Articles

What Cannabis Patent Applicants Can Learn From Biopharma

Law360 January 17, 2019

In the News

3 Takeaways From The PTAB’s Cannabis Experience

Law360 January 11, 2019

Speaking Engagement

Microbiome R&D and Business Collaboration Forum: USA

October 29, 2018 12:00 AM - 11:59 PM PST

Books and Chapters

U.S. Biotechnology Patent Law, 2018-2019 Edition

Thomson Reuters October 10, 2018

Speaking Engagement

USPTO Post-Grant Patent Trials 2018: Change & Recalibration (New York)

September 21, 2018 9:00 AM - 11:59 PM PST

In the News

Fed. Circ. Impeding Biopharma Innovation, Justices Told

Law360 August 29, 2018

In the News

Seeking outsized results

The Boston Globe June 8, 2018

Global Patent Prosecution

Global Patent Prosecution Newsletter – April 2018

April 12, 2018

Bylined Articles

Patents and Patentability in Taiwan

Sterne, Kessler, Goldstein & Fox April 11, 2018

Bylined Articles

Hatch-Waxman goes to Taiwan

Sterne, Kessler, Goldstein & Fox April 11, 2018

In the News

Biologic Fights Drive PTAB Drug Challenges To Record High

Law360 February 8, 2018

Global Patent Prosecution

Global Patent Prosecution Newsletter – January 2018

January 10, 2018

Bylined Articles

Obviousness-Type Double Patenting Dangers in the U.S.

Sterne, Kessler, Goldstein & Fox January 10, 2018

Bylined Articles

Worldwide Divisional Strategy Considerations

Sterne, Kessler, Goldstein & Fox January 10, 2018

In the News

Patent Cases To Watch In 2018

Law360 January 1, 2018

Global Patent Prosecution

Global Patent Prosecution Newsletter – December 2017

December 18, 2017

Bylined Articles

Bolar Exemptions in North America

Sterne, Kessler, Goldstein & Fox December 18, 2017

Bylined Articles

Bolar Exemption in Europe and Asia

Sterne, Kessler, Goldstein & Fox December 18, 2017

Bylined Articles

Worldwide Bolar-type Provisions*

Sterne, Kessler, Goldstein & Fox December 18, 2017

Global Patent Prosecution

Global Patent Prosecution Newsletter – November 2017

November 13, 2017

Bylined Articles

Proposed Emergency Patent Grant Measures in Brazil

Sterne, Kessler, Goldstein & Fox November 13, 2017

Bylined Articles

Statistics on the Backlog Problem and “Fast-Track” Options in Brazil

Sterne, Kessler, Goldstein & Fox November 13, 2017

Bylined Articles

Enforcing Patents in Brazil: An Injunction Paradise?

Sterne, Kessler, Goldstein & Fox November 13, 2017

Bylined Articles

How District Courts Treat Patent Eligibility In Life Sciences

Law360 October 20, 2017

Global Patent Prosecution

Global Patent Prosecution Newsletter – October 2017

October 16, 2017

Bylined Articles

March-in Rights and Compulsory License in the United States

Sterne, Kessler, Goldstein & Fox October 16, 2017

Bylined Articles

Compulsory Licensing of Biopharmaceutical Inventions

Sterne, Kessler, Goldstein & Fox October 16, 2017

Global Patent Prosecution

Global Patent Prosecution Newsletter – September 2017

September 15, 2017

Bylined Articles

Recent Trends on the U.S. Doctrine of Equivalents

Sterne, Kessler, Goldstein & Fox September 15, 2017

Bylined Articles

A Seismic Shift in UK Patent Infringement Law – Actavis v. Eli Lilly

Sterne, Kessler, Goldstein & Fox September 15, 2017

Bylined Articles

Doctrine of Equivalents and Prosecution History Estoppel Around the World

Sterne, Kessler, Goldstein & Fox September 15, 2017

Speaking Engagement

MIP Life Sciences Forum

September 13, 2017

Global Patent Prosecution

Global Patent Prosecution Newsletter – August 2017

August 15, 2017

Bylined Articles

Patent Term Extension Consideration for BioPharma Patents

Sterne, Kessler, Goldstein & Fox August 15, 2017

Bylined Articles

Considerations for Developing a Global Patent Term Extension Strategy

Sterne, Kessler, Goldstein & Fox August 15, 2017

Bylined Articles

Global Patent Term Extension/Supplementary Protection Certificate Provisions

Sterne, Kessler, Goldstein & Fox August 15, 2017

Bylined Articles

Divided Infringement After Eli Lilly V. Teva

Law360 April 18, 2017

Bylined Articles

Top 5 PTAB Tips for Big Pharma

New Jersey Law Journal April 3, 2017

In the News

Defense to Myriad Patent Infringement Claim Now Moved to Patent Trial and Appeal Board

Bloomberg BNA Patent, Trademark & Copyright Law Daily Bulletin August 20, 2014